Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors
Status:
Unknown status
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
Single arm, open label, Phase I, dose-escalation study of indibulin in combination with
erlotinib in subjects with advanced histologically confirmed, solid tumors for which no
standard therapy exists and for whom treatment with erlotinib is considered medically
acceptable.